Derazantinib Uses, Dosage, Side Effects and more
Derazantinib is under investigation in clinical trial NCT03230318 (Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma).
| Attribute | Details |
|---|---|
| Trade Name | Derazantinib |
| Generic | Derazantinib |
| Derazantinib Other Names | Derazantinib |
| Type | |
| Formula | C29H29FN4O |
| Weight | Average: 468.576 Monoisotopic: 468.232539733 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
